ClinicalTrials.Veeva

Menu

Prostate Artery Embolization for Symptomatic Benign Prostatic Hyperplasia

The Chinese University of Hong Kong logo

The Chinese University of Hong Kong

Status

Completed

Conditions

Benign Prostate Hyperplasia

Treatments

Procedure: Prostate artery embolization (PAE)

Study type

Interventional

Funder types

Other

Identifiers

NCT02822924
VIR-13-05

Details and patient eligibility

About

The objective is to evaluate the clinical effectiveness and safety of PAE in treating patients with BPH.

Full description

Benign prostatic hyperplasia (BPH), non-malignant enlargement of the prostate, is a common condition among elderly men with a prevalence increasing with age. When sufficiently large, the hyperplastic nodules compress the urethral canal to cause obstruction of the urethra and interfere the normal flow of urine, leading to symptoms of urinary hesitancy, frequent urination, increased risk of urinary tract infections and urinary retention. While medication is often prescribed as the first treatment option, it often does not adequately restore normal urine flow. Many patients being treated with medication may not achieve sustained improvement in symptoms, or they may stop taking the medication because of side effects, therefore other forms of treatments may be necessary. Although surgery with transurethral resection of prostate (TURP) is a benchmark for BPH treatment, it involves insertion of an endoscope is inserted through the penis, and removal of the prostate piece by piece. While considered a safe technique with a mortality rate below 0.25%, it is not without adverse events. The most frequent complications are ejaculatory disorders (up to 80%), early urinary incontinence (30 to 40%), acute urinary retention caused by blood clots (2 to 5%), sexual impotence (up to 5%), and the need for blood transfusions (0.4 to 7%). Patients who have undergone TURP require surgical retreatment for lower urinary tract symptoms in 3 to 14.5% of cases. Others include infection and urethral stricture. Therefore TURP is only recommended for complicated or severe BPH due to its adverse effects. Prostatic artery embolization (PAE) is a potentially promising, minimally invasive alternative procedure for BPH. Results from early studies showed that PAE might be a safe and effective treatment for BPH.

Enrollment

82 patients

Sex

Male

Ages

50 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age between 50 and 80 years old.
  2. Suffered from lower urinary tract symptoms with International Prostate Symptom Score (IPSS) ≥13, despite medical treatment with alpha-blockers for at least 6 months, or
  3. Suffered from lower urinary tract symptoms with International Prostate Symptom Score (IPSS) ≥13, for whom medication is contraindicated, not tolerated or refused, or
  4. Patients with history of acute retention of urine with or without previous treatment with Alpha-blockers.
  5. Patients with QOL score ≥3.
  6. Patients with Urine flow rate < 15ml/second or acute urinary retention.
  7. Patients with evidence of prostatic enlargement determined by digital rectal examination or ultrasonography (USG), with a prostate size of not less than 40 grams.

Exclusion criteria

  1. Active urinary tract infection
  2. Biopsy proven prostate or bladder cancer, or any recent cancer within 5 years other than basal or squamous cell skin cancer
  3. Bladder atonia, neurogenic bladder disorder or other neurological disorder that is impacting bladder function (e.g. multiple sclerosis, Parkinson's disease, spinal cord injuries, etc)
  4. Urethral stricture, bladder neck contracture, sphincter abnormalities, urinary obstruction due to causes other than BPH, or other potentially confounding bladder or urethral disease or condition
  5. Prostate size <40 grams on CT or MRI
  6. Previous non-medical BPH treatment, including surgery, TURP, needle ablation, microwave or laser therapy, balloon dilation, stent implantation, or any other invasive treatment to the prostate
  7. Any known condition that limits catheter-based intervention or is a contraindication to embolization, such as intolerance to a vessel occlusion procedure or severe atherosclerosis.
  8. Unable to have MRI imaging (e.g. metal implant including pacemaker, replacement joint, etc)
  9. Cardiac condition including congestive heart failure or arrhythmia, uncontrolled diabetes mellitus, significant respiratory disease or known immunosuppression which required hospitalization within the previous 6 months
  10. Baseline serum creatinine level > 160 umol/L
  11. Known upper tract renal disease
  12. Cystolithiasis or chronic hematuria within 3 months prior to study treatment
  13. Active prostatitis
  14. Previous rectal surgery other than hemorrhoidectomy, or history of rectal disease
  15. History of pelvic irradiation or radical pelvic surgery
  16. Coagulation disturbances not normalized by medical treatment
  17. Known major iliac arterial occlusive disease
  18. Allergy to iodinated contrast agents
  19. Hypersensitivity to gelatin products

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

82 participants in 1 patient group

Prostate artery embolization treatment
Other group
Description:
Prostatic artery embolization (PAE) as a new treatment technology is a potentially promising, minimally invasive alternative procedure for BPH, which has been shown to be safe and effective in both animal models and clinical trials.
Treatment:
Procedure: Prostate artery embolization (PAE)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems